Alzheimer's disease neuropathology is exacerbated following traumatic brain injury. Neuroprotection by co-administration of nanowired mesenchymal stem cells and cerebrolysin with monoclonal antibodies to amyloid beta peptide.
Alzheimer's disease
Brain pathology
Cerebrolysin
Mesenchymal stem cells
Nanomedicine
Nanowired delivery
Traumatic brain injury
Journal
Progress in brain research
ISSN: 1875-7855
Titre abrégé: Prog Brain Res
Pays: Netherlands
ID NLM: 0376441
Informations de publication
Date de publication:
2021
2021
Historique:
entrez:
25
9
2021
pubmed:
26
9
2021
medline:
25
11
2021
Statut:
ppublish
Résumé
Military personnel are prone to traumatic brain injury (TBI) that is one of the risk factors in developing Alzheimer's disease (AD) at a later stage. TBI induces breakdown of the blood-brain barrier (BBB) to serum proteins into the brain and leads to extravasation of plasma amyloid beta peptide (ΑβP) into the brain fluid compartments causing AD brain pathology. Thus, there is a need to expand our knowledge on the role of TBI in AD. In addition, exploration of the novel roles of nanomedicine in AD and TBI for neuroprotection is the need of the hour. Since stem cells and neurotrophic factors play important roles in TBI and in AD, it is likely that nanodelivery of these agents exert superior neuroprotection in TBI induced exacerbation of AD brain pathology. In this review, these aspects are examined in details based on our own investigations in the light of current scientific literature in the field. Our observations show that TBI exacerbates AD brain pathology and TiO
Identifiants
pubmed: 34560919
pii: S0079-6123(21)00099-6
doi: 10.1016/bs.pbr.2021.04.008
pii:
doi:
Substances chimiques
Amino Acids
0
Amyloid beta-Peptides
0
Antibodies, Monoclonal
0
Neuroprotective Agents
0
cerebrolysin
37KZM6S21G
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1-97Subventions
Organisme : NIA NIH HHS
ID : R01 AG028679
Pays : United States
Informations de copyright
Copyright © 2021 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Conflict of interest There is no conflict of interest between any entity and/or organization mentioned here.